The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Leisi ZhangYong ZhouKai ChenPengcheng ShiYin LiManman DengZhiwu JiangXiangmeng WangPeng LiBing XuPublished in: Targeted oncology (2018)
AT101 effectively eliminates LSCs in vitro through the induction of DNA damage and activation of the intrinsic apoptotic pathway. AT101 is effective towards leukemic cells from patients with adverse prognostic factors, suggesting that AT101 could have the potential as an alternative salvage therapy for the treatment of relapsed and refractory AML.
Keyphrases
- dna damage
- prognostic factors
- acute myeloid leukemia
- cell death
- oxidative stress
- dna repair
- acute lymphoblastic leukemia
- anti inflammatory
- diffuse large b cell lymphoma
- allogeneic hematopoietic stem cell transplantation
- multiple myeloma
- hodgkin lymphoma
- combination therapy
- climate change
- replacement therapy
- adverse drug
- drug induced